/* 배경화면 투명도 제거 설정 */

[AHA 2013] Impact of Atorvastatin on Development of New-onset Diabetes Mellitus in Asian Population: Three-year Clinical Follow up Results

b bowl 2014.01.30 16:14 579 0 0

Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation.

Core 7. Vascular Disease: Biology and Clinical Science

Session Title: Peripheral Vascular Disease: Metabolic Disorders

Abstract 13414: Impact of Atorvastatin on Development of New-onset Diabetes Mellitus in Asian Population: Three-year Clinical Follow up Results

Yoonjee Park; Seung-Woon Rha; Byoung Geol Choi; Se Yeon Choi; Raghavender Goud Akkala; Sun ki Lee; Ji Bak Kim; Sung Il Im; Jin Oh Na; Cheol Ung Choi; Hong Euy Lim; Jin Won Kim; Eung Ju Kim; Chang Gyu Park; Hong Seog Seo; Dong Joo Oh

Cardiovascular Cntr, Korea Univ Guro Hosp, Seoul, Korea, Republic of

Background: Although statin therapy is beneficial for vascular diseases, the relationship between statin therapy and incidence of new-onset diabetes mellitus (DM) remains limited data. We evaluated the impact of chronic atorvastatin therapy on the development of new-onset DM from 5-year clinical follow up database in Asian population.

Methods: From January 2004 to September 2009, a total of 3,566 consecutive patients who did not have DM were enrolled. New-onset DM was defined as having a fasting blood glucose ≥126mg/dL or HbA1c ≥6.5%. Baseline characteristics between the atorvastatin and the control group were propensity score matched (PSM, C-statistics=0.851). Three-year cumulative incidence of new-onset DM was compared between the two groups.

Results: At baseline, patients in the Atorvastatin group had higher prevalence of elderly, male gender, dyslipidemia, coronary artery disease, smoking history, alcoholic history, higher levels of HbA1c and lower levels of HDL-C. Higher incidence of new-onset DM in the Atorvastatin group (5.8% vs. 2.1%, p<0.001) was observed up to 3 years. Adjusted with cox-regression analysis, atorvastatin use remained as an independent predictor of new-onset DM (OR=2.30, 95% CI 1.40 - 3.77, p=0.001).

Conclusions: In our study, chronic atorvastatin therapy was associated with increased incidence of new-onset DM at 3 years clinical follow up.

Formula

Author Disclosures: Y. Park: None. S. Rha: None. B. Choi: None. S. Choi:None. R. Akkala: None. S. Lee: None. J. Kim: None. S. Im: None. J. Na: None.C. Choi: None. H. Lim: None. J. Kim: None. E. Kim: None. C. Park: None. H. Seo: None. D. Oh: None.


Key Words: Type 2 Diabetes

추천 0 공유 · 더보기 목록

댓글 0